Price T Rowe Associates Inc. MD Buys 5,726 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI)

Price T Rowe Associates Inc. MD boosted its holdings in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI) by 42.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 19,083 shares of the biopharmaceutical company’s stock after purchasing an additional 5,726 shares during the quarter. Price T Rowe Associates Inc. MD’s holdings in Puma Biotechnology were worth $59,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of PBYI. JPMorgan Chase & Co. raised its stake in shares of Puma Biotechnology by 169.5% in the third quarter. JPMorgan Chase & Co. now owns 48,493 shares of the biopharmaceutical company’s stock valued at $124,000 after acquiring an additional 30,499 shares during the period. SG Americas Securities LLC boosted its holdings in shares of Puma Biotechnology by 83.9% in the 4th quarter. SG Americas Securities LLC now owns 24,668 shares of the biopharmaceutical company’s stock valued at $75,000 after buying an additional 11,252 shares in the last quarter. Barclays PLC boosted its holdings in shares of Puma Biotechnology by 146.5% in the 3rd quarter. Barclays PLC now owns 78,021 shares of the biopharmaceutical company’s stock valued at $199,000 after buying an additional 46,370 shares in the last quarter. Wells Fargo & Company MN boosted its stake in Puma Biotechnology by 36.5% in the 4th quarter. Wells Fargo & Company MN now owns 22,929 shares of the biopharmaceutical company’s stock worth $70,000 after purchasing an additional 6,126 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in Puma Biotechnology by 19.5% in the 4th quarter. Bank of New York Mellon Corp now owns 331,853 shares of the biopharmaceutical company’s stock worth $1,012,000 after purchasing an additional 54,150 shares in the last quarter. Hedge funds and other institutional investors own 61.29% of the company’s stock.

Puma Biotechnology Stock Up 3.4%

Shares of PBYI opened at $3.39 on Monday. The firm has a market cap of $168.25 million, a P/E ratio of 7.06 and a beta of 1.29. Puma Biotechnology, Inc. has a 12-month low of $2.23 and a 12-month high of $4.83. The company’s 50-day moving average price is $3.07 and its 200 day moving average price is $3.05. The company has a current ratio of 1.42, a quick ratio of 1.40 and a debt-to-equity ratio of 0.46.

Puma Biotechnology (NASDAQ:PBYI) last issued its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported $0.39 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.10 by $0.29. The company had revenue of $59.10 million for the quarter, compared to analyst estimates of $52.50 million. Puma Biotechnology had a net margin of 9.56% and a return on equity of 41.60%. On average, sell-side analysts forecast that Puma Biotechnology, Inc. will post 0.31 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on PBYI shares. HC Wainwright reissued a “buy” rating and set a $7.00 price target on shares of Puma Biotechnology in a research report on Friday, February 28th. StockNews.com raised shares of Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a research note on Sunday, May 11th.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.